<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240320141009&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240320141009&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 20 Mar 2024 18:10:10 +0000</lastbuilddate>
<pubDate>Wed, 20 Mar 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>JAMA Cardiology-The Year in Review, 2023</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38506885/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240320141009&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Mar 20. doi: 10.1001/jamacardio.2024.0340. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38506885/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240320141009&v=2.18.0.post9+e462414">38506885</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0340>10.1001/jamacardio.2024.0340</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38506885</guid>
<pubDate>Wed, 20 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Robert O Bonow</dc:creator>
<dc:date>2024-03-20</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>JAMA Cardiology-The Year in Review, 2023</dc:title>
<dc:identifier>pmid:38506885</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0340</dc:identifier>
</item>
<item>
<title>Consolidating NRMP Fellowship Matches to Enhance the Applicant Experience</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38506882/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240320141009&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Mar 20. doi: 10.1001/jamacardio.2024.0130. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38506882/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240320141009&v=2.18.0.post9+e462414">38506882</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0130>10.1001/jamacardio.2024.0130</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38506882</guid>
<pubDate>Wed, 20 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Jeanette L Calli</dc:creator>
<dc:creator>Laurie S Curtin</dc:creator>
<dc:date>2024-03-20</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Consolidating NRMP Fellowship Matches to Enhance the Applicant Experience</dc:title>
<dc:identifier>pmid:38506882</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0130</dc:identifier>
</item>
<item>
<title>Electrocardiographic Findings in Female Professional Basketball Athletes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38506880/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240320141009&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: This cross-sectional study provides reference ECG data for elite female basketball athletes. International criteria-defined training-related findings were common, whereas abnormal ECG findings were rare in this athlete group. These reference data may assist basketball programs and health care professionals using ECGs in screening for female athletes and may be used as a stimulus for future female-specific ECG inquiries.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Mar 20. doi: 10.1001/jamacardio.2024.0207. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Previous studies of professional basketball athletes have characterized manifestations of athletic remodeling by echocardiography and electrocardiography (ECG) in males and echocardiography in females. There is a paucity of female, basketball-specific ECG data.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To generate reference range ECG data for female professional basketball athletes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This is a cross-sectional study of ECGs performed on female professional basketball athletes. The Women's National Basketball Association mandates annual preseason ECGs and echocardiograms for each athlete and has partnered with Columbia University Irving Medical Center to annually review these studies. Data for this study were collected during preseason ECG and echocardiography cardiac screening between April and May 2022. Data analysis was performed between February and July 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: Athlete ECGs and echocardiograms were sent to Columbia University Irving Medical Center for core lab analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Quantitative ECG variables were measured. ECG data were qualitatively analyzed for training-related and abnormal findings using the International Recommendations for Electrocardiographic Interpretation in Athletes. Findings from ECGs were compared with corresponding echocardiographic data.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: There were a total of 173 athletes (mean [SD] age 26.5 [4.1] years; mean [SD] height, 183.4 [9.1] cm; mean [SD] body surface area, 2.0 [0.2] m2), including 129 Black athletes (74.5%) and 40 White athletes (23.1%). By international criteria, 136 athletes (78.6%) had training-related ECG changes and 8 athletes (4.6%) had abnormal ECG findings. Among athletes with at least 1 training-related ECG finding, left ventricular structural adaptations associated with athletic remodeling were present in 64 athletes (47.1%). Increased relative wall thickness, reflecting concentric left ventricular geometry, was more prevalent in athletes with the repolarization variant demonstrating convex ST elevation combined with T-wave inversions in leads V1 to V4 (6 of 12 athletes [50.0%]) than in athletes with early repolarization (5 of 42 athletes [11.9%]) (odds ratio, 7.40; 95% CI, 1.71-32.09; P = .01). Abnormal ECG findings included T-wave inversions (3 athletes [1.7%]), Q waves (2 athletes [1.2%]), prolonged QTc interval (2 athletes [1.2%]), and frequent premature ventricular contractions (1 athlete [0.6%]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: This cross-sectional study provides reference ECG data for elite female basketball athletes. International criteria-defined training-related findings were common, whereas abnormal ECG findings were rare in this athlete group. These reference data may assist basketball programs and health care professionals using ECGs in screening for female athletes and may be used as a stimulus for future female-specific ECG inquiries.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38506880/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240320141009&v=2.18.0.post9+e462414">38506880</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0207>10.1001/jamacardio.2024.0207</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38506880</guid>
<pubDate>Wed, 20 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Bradley S Lander</dc:creator>
<dc:creator>Eamon Y Duffy</dc:creator>
<dc:creator>Jessica A Hennessey</dc:creator>
<dc:creator>Sonia Tolani</dc:creator>
<dc:creator>Nidhi Patel</dc:creator>
<dc:creator>Michael S Bohnen</dc:creator>
<dc:creator>Jeffrey J Hsu</dc:creator>
<dc:creator>Alfred Danielian</dc:creator>
<dc:creator>Ankit B Shah</dc:creator>
<dc:creator>Marci Goolsby</dc:creator>
<dc:creator>Matthew W Martinez</dc:creator>
<dc:creator>Dermot Phelan</dc:creator>
<dc:creator>David J Engel</dc:creator>
<dc:date>2024-03-20</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Electrocardiographic Findings in Female Professional Basketball Athletes</dc:title>
<dc:identifier>pmid:38506880</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0207</dc:identifier>
</item>
<item>
<title>JAMA Cardiology Peer Reviewers in 2023</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38506821/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240320141009&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Mar 20:e240155. doi: 10.1001/jamacardio.2024.0155. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38506821/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240320141009&v=2.18.0.post9+e462414">38506821</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0155>10.1001/jamacardio.2024.0155</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38506821</guid>
<pubDate>Wed, 20 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-20</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>JAMA Cardiology Peer Reviewers in 2023</dc:title>
<dc:identifier>pmid:38506821</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0155</dc:identifier>
</item>
<item>
<title>Type 2 Myocardial Infarction-Poorly Understood, Underevaluated, and Too Often Ignored</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38506815/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240320141009&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Mar 20. doi: 10.1001/jamacardio.2024.0127. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38506815/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240320141009&v=2.18.0.post9+e462414">38506815</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0127>10.1001/jamacardio.2024.0127</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38506815</guid>
<pubDate>Wed, 20 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>James A de Lemos</dc:creator>
<dc:creator>Bertil Lindahl</dc:creator>
<dc:creator>Nicholas L Mills</dc:creator>
<dc:date>2024-03-20</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Type 2 Myocardial Infarction-Poorly Understood, Underevaluated, and Too Often Ignored</dc:title>
<dc:identifier>pmid:38506815</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0127</dc:identifier>
</item>
<item>
<title>Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient-Level Meta-Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38506796/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240320141009&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: This systematic review and meta-analysis found that ticagrelor monotherapy was noninferior to DAPT for all-cause death, MI, or stroke and superior for major bleeding and NACE. Clopidogrel monotherapy was similarly associated with reduced bleeding but was not noninferior to DAPT for all-cause death, MI, or stroke, largely because of risk observed in 1 trial that exclusively included East Asian patients and a hazard that was driven by an excess of noncardiovascular...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Mar 20. doi: 10.1001/jamacardio.2024.0133. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Among patients undergoing percutaneous coronary intervention (PCI), it remains unclear whether the treatment efficacy of P2Y12 inhibitor monotherapy after a short course of dual antiplatelet therapy (DAPT) depends on the type of P2Y12 inhibitor.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To assess the risks and benefits of ticagrelor monotherapy or clopidogrel monotherapy compared with standard DAPT after PCI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DATA SOURCES: MEDLINE, Embase, TCTMD, and the European Society of Cardiology website were searched from inception to September 10, 2023, without language restriction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">STUDY SELECTION: Included studies were randomized clinical trials comparing P2Y12 inhibitor monotherapy with DAPT on adjudicated end points in patients without indication to oral anticoagulation undergoing PCI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DATA EXTRACTION AND SYNTHESIS: Patient-level data provided by each trial were synthesized into a pooled dataset and analyzed using a 1-step mixed-effects model. The study is reported following the Preferred Reporting Items for Systematic Review and Meta-Analyses of Individual Participant Data.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary objective was to determine noninferiority of ticagrelor or clopidogrel monotherapy vs DAPT on the composite of death, myocardial infarction (MI), or stroke in the per-protocol analysis with a 1.15 margin for the hazard ratio (HR). Key secondary end points were major bleeding and net adverse clinical events (NACE), including the primary end point and major bleeding.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Analyses included 6 randomized trials including 25 960 patients undergoing PCI, of whom 24 394 patients (12 403 patients receiving DAPT; 8292 patients receiving ticagrelor monotherapy; 3654 patients receiving clopidogrel monotherapy; 45 patients receiving prasugrel monotherapy) were retained in the per-protocol analysis. Trials of ticagrelor monotherapy were conducted in Asia, Europe, and North America; trials of clopidogrel monotherapy were all conducted in Asia. Ticagrelor was noninferior to DAPT for the primary end point (HR, 0.89; 95% CI, 0.74-1.06; P for noninferiority = .004), but clopidogrel was not noninferior (HR, 1.37; 95% CI, 1.01-1.87; P for noninferiority >; .99), with this finding driven by noncardiovascular death. The risk of major bleeding was lower with both ticagrelor (HR, 0.47; 95% CI, 0.36-0.62; P &lt; .001) and clopidogrel monotherapy (HR, 0.49; 95% CI, 0.30-0.81; P = .006; P for interaction = 0.88). NACE were lower with ticagrelor (HR, 0.74; 95% CI, 0.64-0.86, P &lt; .001) but not with clopidogrel monotherapy (HR, 1.00; 95% CI, 0.78-1.28; P = .99; P for interaction = .04).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: This systematic review and meta-analysis found that ticagrelor monotherapy was noninferior to DAPT for all-cause death, MI, or stroke and superior for major bleeding and NACE. Clopidogrel monotherapy was similarly associated with reduced bleeding but was not noninferior to DAPT for all-cause death, MI, or stroke, largely because of risk observed in 1 trial that exclusively included East Asian patients and a hazard that was driven by an excess of noncardiovascular death.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38506796/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240320141009&v=2.18.0.post9+e462414">38506796</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0133>10.1001/jamacardio.2024.0133</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38506796</guid>
<pubDate>Wed, 20 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Marco Valgimigli</dc:creator>
<dc:creator>Felice Gragnano</dc:creator>
<dc:creator>Mattia Branca</dc:creator>
<dc:creator>Anna Franzone</dc:creator>
<dc:creator>Bruno R da Costa</dc:creator>
<dc:creator>Usman Baber</dc:creator>
<dc:creator>Takeshi Kimura</dc:creator>
<dc:creator>Yangsoo Jang</dc:creator>
<dc:creator>Joo-Yong Hahn</dc:creator>
<dc:creator>Qiang Zhao</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>Charles M Gibson</dc:creator>
<dc:creator>Hirotoshi Watanabe</dc:creator>
<dc:creator>Byeong-Keuk Kim</dc:creator>
<dc:creator>Young Bin Song</dc:creator>
<dc:creator>Yunpeng Zhu</dc:creator>
<dc:creator>Pascal Vranckx</dc:creator>
<dc:creator>Shamir Mehta</dc:creator>
<dc:creator>Kenji Ando</dc:creator>
<dc:creator>Sung Jin Hong</dc:creator>
<dc:creator>Hyeon-Cheol Gwon</dc:creator>
<dc:creator>Patrick W Serruys</dc:creator>
<dc:creator>George D Dangas</dc:creator>
<dc:creator>Eùgene P McFadden</dc:creator>
<dc:creator>Dominick J Angiolillo</dc:creator>
<dc:creator>Dik Heg</dc:creator>
<dc:creator>Paolo Calabrò</dc:creator>
<dc:creator>Peter Jüni</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Single Versus Dual Antiplatelet Therapy (Sidney-3) Collaboration</dc:creator>
<dc:date>2024-03-20</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient-Level Meta-Analysis</dc:title>
<dc:identifier>pmid:38506796</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0133</dc:identifier>
</item>
<item>
<title>AKAP12 Upregulation Associates With PDE8A to Accelerate Cardiac Dysfunction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38506047/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240320141009&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: AKAP12 upregulation in cardiac tissue is associated with accelerated cardiac dysfunction through the AKAP12-PDE8 axis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar 20. doi: 10.1161/CIRCRESAHA.123.323655. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In heart failure, signaling downstream the β2-adrenergic receptor is critical. Sympathetic stimulation of β2-adrenergic receptor alters cAMP (cyclic adenosine 3',5'-monophosphate) and triggers PKA (protein kinase A)-dependent phosphorylation of proteins that regulate cardiac function. cAMP levels are regulated in part by PDEs (phosphodiesterases). Several AKAPs (A kinase anchoring proteins) regulate cardiac function and are proposed as targets for precise pharmacology. AKAP12 is expressed in the heart and has been reported to directly bind β2-adrenergic receptor, PKA, and PDE4D. However, its roles in cardiac function are unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: cAMP accumulation in real time downstream of the β2-adrenergic receptor was detected for 60 minutes in live cells using the luciferase-based biosensor (GloSensor) in AC16 human-derived cardiomyocyte cell lines overexpressing AKAP12 versus controls. Cardiomyocyte intracellular calcium and contractility were studied in adult primary cardiomyocytes from male and female mice overexpressing cardiac AKAP12 (AKAP12<sup>OX</sup>) and wild-type littermates postacute treatment with 100-nM isoproterenol. Systolic cardiac function was assessed in mice after 14 days of subcutaneous isoproterenol administration (60 mg/kg per day). AKAP12 gene and protein expression levels were evaluated in left ventricular samples from patients with end-stage heart failure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: AKAP12 upregulation significantly reduced total intracellular cAMP levels in AC16 cells through PDE8. Adult primary cardiomyocytes from AKAP12<sup>OX</sup> mice had significantly reduced contractility and impaired calcium handling in response to isoproterenol, which was reversed in the presence of the selective PDE8 inhibitor (PF-04957325). AKAP12<sup>OX</sup> mice had deteriorated systolic cardiac function and enlarged left ventricles. Patients with end-stage heart failure had upregulated gene and protein levels of AKAP12.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: AKAP12 upregulation in cardiac tissue is associated with accelerated cardiac dysfunction through the AKAP12-PDE8 axis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38506047/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240320141009&v=2.18.0.post9+e462414">38506047</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323655>10.1161/CIRCRESAHA.123.323655</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38506047</guid>
<pubDate>Wed, 20 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Hanan Qasim</dc:creator>
<dc:creator>Mehrdad Rajaei</dc:creator>
<dc:creator>Ying Xu</dc:creator>
<dc:creator>Arfaxad Reyes-Alcaraz</dc:creator>
<dc:creator>Hala Y Abdelnasser</dc:creator>
<dc:creator>M David Stewart</dc:creator>
<dc:creator>Satadru K Lahiri</dc:creator>
<dc:creator>Xander H T Wehrens</dc:creator>
<dc:creator>Bradley K McConnell</dc:creator>
<dc:date>2024-03-20</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>AKAP12 Upregulation Associates With PDE8A to Accelerate Cardiac Dysfunction</dc:title>
<dc:identifier>pmid:38506047</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323655</dc:identifier>
</item>
<item>
<title>Virus-Induced Acute Respiratory Distress Syndrome Causes Cardiomyopathy Through Eliciting Inflammatory Responses in the Heart</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38506045/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240320141009&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our data suggest that viral ARDS promotes cardiac inflammation by expanding the CCR2^(+) macrophage subset, and the associated cardiac phenotypes in mice can be elicited by activating the host immune system even without viral presence in the heart.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 20. doi: 10.1161/CIRCULATIONAHA.123.066433. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Viral infections can cause acute respiratory distress syndrome (ARDS), systemic inflammation, and secondary cardiovascular complications. Lung macrophage subsets change during ARDS, but the role of heart macrophages in cardiac injury during viral ARDS remains unknown. Here we investigate how immune signals typical for viral ARDS affect cardiac macrophage subsets, cardiovascular health, and systemic inflammation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We assessed cardiac macrophage subsets using immunofluorescence histology of autopsy specimens from 21 patients with COVID-19 with SARS-CoV-2-associated ARDS and 33 patients who died from other causes. In mice, we compared cardiac immune cell dynamics after SARS-CoV-2 infection with ARDS induced by intratracheal instillation of Toll-like receptor ligands and an ACE2 (angiotensin-converting enzyme 2) inhibitor.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In humans, SARS-CoV-2 increased total cardiac macrophage counts and led to a higher proportion of CCR2<sup>+</sup> (C-C chemokine receptor type 2 positive) macrophages. In mice, SARS-CoV-2 and virus-free lung injury triggered profound remodeling of cardiac resident macrophages, recapitulating the clinical expansion of CCR2<sup>+</sup> macrophages. Treating mice exposed to virus-like ARDS with a tumor necrosis factor α-neutralizing antibody reduced cardiac monocytes and inflammatory MHCII<sup>lo</sup> CCR2<sup>+</sup> macrophages while also preserving cardiac function. Virus-like ARDS elevated mortality in mice with pre-existing heart failure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our data suggest that viral ARDS promotes cardiac inflammation by expanding the CCR2<sup>+</sup> macrophage subset, and the associated cardiac phenotypes in mice can be elicited by activating the host immune system even without viral presence in the heart.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38506045/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240320141009&v=2.18.0.post9+e462414">38506045</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066433>10.1161/CIRCULATIONAHA.123.066433</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38506045</guid>
<pubDate>Wed, 20 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Jana Grune</dc:creator>
<dc:creator>Geetika Bajpai</dc:creator>
<dc:creator>Pervin Tülin Ocak</dc:creator>
<dc:creator>Eva Kaufmann</dc:creator>
<dc:creator>Kyle Mentkowksi</dc:creator>
<dc:creator>Steffen Pabel</dc:creator>
<dc:creator>Nina Kumowski</dc:creator>
<dc:creator>Fadi E Pulous</dc:creator>
<dc:creator>Kim A Tran</dc:creator>
<dc:creator>David Rohde</dc:creator>
<dc:creator>Shuang Zhang</dc:creator>
<dc:creator>Yoshiko Iwamoto</dc:creator>
<dc:creator>Gregory R Wojtkiewicz</dc:creator>
<dc:creator>Claudio Vinegoni</dc:creator>
<dc:creator>Ursula Green</dc:creator>
<dc:creator>Filip K Swirski</dc:creator>
<dc:creator>James R Stone</dc:creator>
<dc:creator>Jochen K Lennerz</dc:creator>
<dc:creator>Maziar Divangahi</dc:creator>
<dc:creator>Maarten Hulsmans</dc:creator>
<dc:creator>Matthias Nahrendorf</dc:creator>
<dc:date>2024-03-20</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Virus-Induced Acute Respiratory Distress Syndrome Causes Cardiomyopathy Through Eliciting Inflammatory Responses in the Heart</dc:title>
<dc:identifier>pmid:38506045</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066433</dc:identifier>
</item>
<item>
<title>Deep learning to detect left ventricular structural abnormalities in chest X-rays</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38503537/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240320141009&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Deep learning analysis of CXRs can accurately detect the presence of certain structural abnormalities and may be useful in early identification of patients with LV hypertrophy and dilation. As a resource to promote further innovation, 71 589 CXRs with adjoining echocardiographic labels have been made publicly available.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 20:ehad782. doi: 10.1093/eurheartj/ehad782. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Early identification of cardiac structural abnormalities indicative of heart failure is crucial to improving patient outcomes. Chest X-rays (CXRs) are routinely conducted on a broad population of patients, presenting an opportunity to build scalable screening tools for structural abnormalities indicative of Stage B or worse heart failure with deep learning methods. In this study, a model was developed to identify severe left ventricular hypertrophy (SLVH) and dilated left ventricle (DLV) using CXRs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 71 589 unique CXRs from 24 689 different patients completed within 1 year of echocardiograms were identified. Labels for SLVH, DLV, and a composite label indicating the presence of either were extracted from echocardiograms. A deep learning model was developed and evaluated using area under the receiver operating characteristic curve (AUROC). Performance was additionally validated on 8003 CXRs from an external site and compared against visual assessment by 15 board-certified radiologists.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The model yielded an AUROC of 0.79 (0.76-0.81) for SLVH, 0.80 (0.77-0.84) for DLV, and 0.80 (0.78-0.83) for the composite label, with similar performance on an external data set. The model outperformed all 15 individual radiologists for predicting the composite label and achieved a sensitivity of 71% vs. 66% against the consensus vote across all radiologists at a fixed specificity of 73%.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Deep learning analysis of CXRs can accurately detect the presence of certain structural abnormalities and may be useful in early identification of patients with LV hypertrophy and dilation. As a resource to promote further innovation, 71 589 CXRs with adjoining echocardiographic labels have been made publicly available.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38503537/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240320141009&v=2.18.0.post9+e462414">38503537</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad782>10.1093/eurheartj/ehad782</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38503537</guid>
<pubDate>Tue, 19 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Shreyas Bhave</dc:creator>
<dc:creator>Victor Rodriguez</dc:creator>
<dc:creator>Timothy Poterucha</dc:creator>
<dc:creator>Simukayi Mutasa</dc:creator>
<dc:creator>Dwight Aberle</dc:creator>
<dc:creator>Kathleen M Capaccione</dc:creator>
<dc:creator>Yibo Chen</dc:creator>
<dc:creator>Belinda Dsouza</dc:creator>
<dc:creator>Shifali Dumeer</dc:creator>
<dc:creator>Jonathan Goldstein</dc:creator>
<dc:creator>Aaron Hodes</dc:creator>
<dc:creator>Jay Leb</dc:creator>
<dc:creator>Matthew Lungren</dc:creator>
<dc:creator>Mitchell Miller</dc:creator>
<dc:creator>David Monoky</dc:creator>
<dc:creator>Benjamin Navot</dc:creator>
<dc:creator>Kapil Wattamwar</dc:creator>
<dc:creator>Anoop Wattamwar</dc:creator>
<dc:creator>Kevin Clerkin</dc:creator>
<dc:creator>David Ouyang</dc:creator>
<dc:creator>Euan Ashley</dc:creator>
<dc:creator>Veli K Topkara</dc:creator>
<dc:creator>Mathew Maurer</dc:creator>
<dc:creator>Andrew J Einstein</dc:creator>
<dc:creator>Nir Uriel</dc:creator>
<dc:creator>Shunichi Homma</dc:creator>
<dc:creator>Allan Schwartz</dc:creator>
<dc:creator>Diego Jaramillo</dc:creator>
<dc:creator>Adler J Perotte</dc:creator>
<dc:creator>Pierre Elias</dc:creator>
<dc:date>2024-03-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Deep learning to detect left ventricular structural abnormalities in chest X-rays</dc:title>
<dc:identifier>pmid:38503537</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad782</dc:identifier>
</item>
<item>
<title>RNA damage compartmentalization by DHX9 stress granules</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38503283/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240320141009&amp;v=2.18.0.post9+e462414
      <description>Biomolecules incur damage during stress conditions, and damage partitioning represents a vital survival strategy for cells. Here, we identified a distinct stress granule (SG), marked by dsRNA helicase DHX9, which compartmentalizes ultraviolet (UV)-induced RNA, but not DNA, damage. Our FANCI technology revealed that DHX9 SGs are enriched in damaged intron RNA, in contrast to classical SGs that are composed of mature mRNA. UV exposure causes RNA crosslinking damage, impedes intron splicing and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Mar 7:S0092-8674(24)00231-9. doi: 10.1016/j.cell.2024.02.028. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Biomolecules incur damage during stress conditions, and damage partitioning represents a vital survival strategy for cells. Here, we identified a distinct stress granule (SG), marked by dsRNA helicase DHX9, which compartmentalizes ultraviolet (UV)-induced RNA, but not DNA, damage. Our FANCI technology revealed that DHX9 SGs are enriched in damaged intron RNA, in contrast to classical SGs that are composed of mature mRNA. UV exposure causes RNA crosslinking damage, impedes intron splicing and decay, and triggers DHX9 SGs within daughter cells. DHX9 SGs promote cell survival and induce dsRNA-related immune response and translation shutdown, differentiating them from classical SGs that assemble downstream of translation arrest. DHX9 modulates dsRNA abundance in the DHX9 SGs and promotes cell viability. Autophagy receptor p62 is activated and important for DHX9 SG disassembly. Our findings establish non-canonical DHX9 SGs as a dedicated non-membrane-bound cytoplasmic compartment that safeguards daughter cells from parental RNA damage.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38503283/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240320141009&v=2.18.0.post9+e462414">38503283</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.02.028>10.1016/j.cell.2024.02.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38503283</guid>
<pubDate>Tue, 19 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Yilong Zhou</dc:creator>
<dc:creator>Amol Panhale</dc:creator>
<dc:creator>Maria Shvedunova</dc:creator>
<dc:creator>Mirela Balan</dc:creator>
<dc:creator>Alejandro Gomez-Auli</dc:creator>
<dc:creator>Herbert Holz</dc:creator>
<dc:creator>Janine Seyfferth</dc:creator>
<dc:creator>Martin Helmstädter</dc:creator>
<dc:creator>Séverine Kayser</dc:creator>
<dc:creator>Yuling Zhao</dc:creator>
<dc:creator>Niyazi Umut Erdogdu</dc:creator>
<dc:creator>Iga Grzadzielewska</dc:creator>
<dc:creator>Gerhard Mittler</dc:creator>
<dc:creator>Thomas Manke</dc:creator>
<dc:creator>Asifa Akhtar</dc:creator>
<dc:date>2024-03-19</dc:date>
<dc:source>Cell</dc:source>
<dc:title>RNA damage compartmentalization by DHX9 stress granules</dc:title>
<dc:identifier>pmid:38503283</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.02.028</dc:identifier>
</item>
<item>
<title>Contrasting somatic mutation patterns in aging human neurons and oligodendrocytes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38503282/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240320141009&amp;v=2.18.0.post9+e462414
      <description>Characterizing somatic mutations in the brain is important for disentangling the complex mechanisms of aging, yet little is known about mutational patterns in different brain cell types. Here, we performed whole-genome sequencing (WGS) of 86 single oligodendrocytes, 20 mixed glia, and 56 single neurons from neurotypical individuals spanning 0.4-104 years of age and identified >;92,000 somatic single-nucleotide variants (sSNVs) and small insertions/deletions (indels). Although both cell types...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Mar 11:S0092-8674(24)00227-7. doi: 10.1016/j.cell.2024.02.025. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Characterizing somatic mutations in the brain is important for disentangling the complex mechanisms of aging, yet little is known about mutational patterns in different brain cell types. Here, we performed whole-genome sequencing (WGS) of 86 single oligodendrocytes, 20 mixed glia, and 56 single neurons from neurotypical individuals spanning 0.4-104 years of age and identified >;92,000 somatic single-nucleotide variants (sSNVs) and small insertions/deletions (indels). Although both cell types accumulate somatic mutations linearly with age, oligodendrocytes accumulated sSNVs 81% faster than neurons and indels 28% slower than neurons. Correlation of mutations with single-nucleus RNA profiles and chromatin accessibility from the same brains revealed that oligodendrocyte mutations are enriched in inactive genomic regions and are distributed across the genome similarly to mutations in brain cancers. In contrast, neuronal mutations are enriched in open, transcriptionally active chromatin. These stark differences suggest an assortment of active mutagenic processes in oligodendrocytes and neurons.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38503282/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240320141009&v=2.18.0.post9+e462414">38503282</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.02.025>10.1016/j.cell.2024.02.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38503282</guid>
<pubDate>Tue, 19 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Javier Ganz</dc:creator>
<dc:creator>Lovelace J Luquette</dc:creator>
<dc:creator>Sara Bizzotto</dc:creator>
<dc:creator>Michael B Miller</dc:creator>
<dc:creator>Zinan Zhou</dc:creator>
<dc:creator>Craig L Bohrson</dc:creator>
<dc:creator>Hu Jin</dc:creator>
<dc:creator>Antuan V Tran</dc:creator>
<dc:creator>Vinayak V Viswanadham</dc:creator>
<dc:creator>Gannon McDonough</dc:creator>
<dc:creator>Katherine Brown</dc:creator>
<dc:creator>Yasmine Chahine</dc:creator>
<dc:creator>Brian Chhouk</dc:creator>
<dc:creator>Alon Galor</dc:creator>
<dc:creator>Peter J Park</dc:creator>
<dc:creator>Christopher A Walsh</dc:creator>
<dc:date>2024-03-19</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Contrasting somatic mutation patterns in aging human neurons and oligodendrocytes</dc:title>
<dc:identifier>pmid:38503282</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.02.025</dc:identifier>
</item>
<item>
<title>Macromolecular condensation organizes nucleolar sub-phases to set up a pH gradient</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38503281/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240320141009&amp;v=2.18.0.post9+e462414
      <description>Nucleoli are multicomponent condensates defined by coexisting sub-phases. We identified distinct intrinsically disordered regions (IDRs), including acidic (D/E) tracts and K-blocks interspersed by E-rich regions, as defining features of nucleolar proteins. We show that the localization preferences of nucleolar proteins are determined by their IDRs and the types of RNA or DNA binding domains they encompass. In vitro reconstitutions and studies in cells showed how condensation, which combines...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Mar 13:S0092-8674(24)00232-0. doi: 10.1016/j.cell.2024.02.029. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Nucleoli are multicomponent condensates defined by coexisting sub-phases. We identified distinct intrinsically disordered regions (IDRs), including acidic (D/E) tracts and K-blocks interspersed by E-rich regions, as defining features of nucleolar proteins. We show that the localization preferences of nucleolar proteins are determined by their IDRs and the types of RNA or DNA binding domains they encompass. In vitro reconstitutions and studies in cells showed how condensation, which combines binding and complex coacervation of nucleolar components, contributes to nucleolar organization. D/E tracts of nucleolar proteins contribute to lowering the pH of co-condensates formed with nucleolar RNAs in vitro. In cells, this sets up a pH gradient between nucleoli and the nucleoplasm. By contrast, juxta-nucleolar bodies, which have different macromolecular compositions, featuring protein IDRs with very different charge profiles, have pH values that are equivalent to or higher than the nucleoplasm. Our findings show that distinct compositional specificities generate distinct physicochemical properties for condensates.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38503281/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240320141009&v=2.18.0.post9+e462414">38503281</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.02.029>10.1016/j.cell.2024.02.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38503281</guid>
<pubDate>Tue, 19 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Matthew R King</dc:creator>
<dc:creator>Kiersten M Ruff</dc:creator>
<dc:creator>Andrew Z Lin</dc:creator>
<dc:creator>Avnika Pant</dc:creator>
<dc:creator>Mina Farag</dc:creator>
<dc:creator>Jared M Lalmansingh</dc:creator>
<dc:creator>Tingting Wu</dc:creator>
<dc:creator>Martin J Fossat</dc:creator>
<dc:creator>Wei Ouyang</dc:creator>
<dc:creator>Matthew D Lew</dc:creator>
<dc:creator>Emma Lundberg</dc:creator>
<dc:creator>Michael D Vahey</dc:creator>
<dc:creator>Rohit V Pappu</dc:creator>
<dc:date>2024-03-19</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Macromolecular condensation organizes nucleolar sub-phases to set up a pH gradient</dc:title>
<dc:identifier>pmid:38503281</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.02.029</dc:identifier>
</item>
<item>
<title>A gut-derived hormone regulates cholesterol metabolism</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38503280/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240320141009&amp;v=2.18.0.post9+e462414
      <description>The reciprocal coordination between cholesterol absorption in the intestine and de novo cholesterol synthesis in the liver is essential for maintaining cholesterol homeostasis, yet the mechanisms governing the opposing regulation of these processes remain poorly understood. Here, we identify a hormone, Cholesin, which is capable of inhibiting cholesterol synthesis in the liver, leading to a reduction in circulating cholesterol levels. Cholesin is encoded by a gene with a previously unknown...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Mar 7:S0092-8674(24)00226-5. doi: 10.1016/j.cell.2024.02.024. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The reciprocal coordination between cholesterol absorption in the intestine and de novo cholesterol synthesis in the liver is essential for maintaining cholesterol homeostasis, yet the mechanisms governing the opposing regulation of these processes remain poorly understood. Here, we identify a hormone, Cholesin, which is capable of inhibiting cholesterol synthesis in the liver, leading to a reduction in circulating cholesterol levels. Cholesin is encoded by a gene with a previously unknown function (C7orf50 in humans; 3110082I17Rik in mice). It is secreted from the intestine in response to cholesterol absorption and binds to GPR146, an orphan G-protein-coupled receptor, exerting antagonistic downstream effects by inhibiting PKA signaling and thereby suppressing SREBP2-controlled cholesterol synthesis in the liver. Therefore, our results demonstrate that the Cholesin-GPR146 axis mediates the inhibitory effect of intestinal cholesterol absorption on hepatic cholesterol synthesis. This discovered hormone, Cholesin, holds promise as an effective agent in combating hypercholesterolemia and atherosclerosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38503280/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240320141009&v=2.18.0.post9+e462414">38503280</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.02.024>10.1016/j.cell.2024.02.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38503280</guid>
<pubDate>Tue, 19 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Xiaoli Hu</dc:creator>
<dc:creator>Fengyi Chen</dc:creator>
<dc:creator>Liangjie Jia</dc:creator>
<dc:creator>Aijun Long</dc:creator>
<dc:creator>Ying Peng</dc:creator>
<dc:creator>Xu Li</dc:creator>
<dc:creator>Junfeng Huang</dc:creator>
<dc:creator>Xueyun Wei</dc:creator>
<dc:creator>Xinlei Fang</dc:creator>
<dc:creator>Zihua Gao</dc:creator>
<dc:creator>Mengxian Zhang</dc:creator>
<dc:creator>Xiao Liu</dc:creator>
<dc:creator>Ye-Guang Chen</dc:creator>
<dc:creator>Yan Wang</dc:creator>
<dc:creator>Huijie Zhang</dc:creator>
<dc:creator>Yiguo Wang</dc:creator>
<dc:date>2024-03-19</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A gut-derived hormone regulates cholesterol metabolism</dc:title>
<dc:identifier>pmid:38503280</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.02.024</dc:identifier>
</item>
<item>
<title>LOX-1 and MMP-9 Inhibition Attenuates the Detrimental Effects of Delayed rt-PA Therapy and Improves Outcomes After Acute Ischemic Stroke</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38501247/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240320141009&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our findings indicate that MMP-9 and LOX-1 inhibition attenuates negative aspects of ischemic stroke with an rt-PA therapy, thus resulting in improved neurological function. While no synergistic effect was observed with simultaneous LOX-1 and MMP-9 inhibition, a distinct interaction is evident.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar 19. doi: 10.1161/CIRCRESAHA.123.323371. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Acute ischemic stroke triggers endothelial activation that disrupts vascular integrity and increases hemorrhagic transformation leading to worsened stroke outcomes. rt-PA (recombinant tissue-type plasminogen activator) is an effective treatment; however, its use is limited due to a restricted time window and hemorrhagic transformation risk, which in part may involve activation of MMPs (matrix metalloproteinases) mediated through LOX-1 (lectin-like oxLDL [oxidized low-density lipoprotein] receptor 1). This study's overall aim was to evaluate the therapeutic potential of novel MMP-9 (matrix metalloproteinase 9) and LOX-1 inhibitors in combination with rt-PA to improve stroke outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A rat thromboembolic stroke model was utilized to investigate the impact of rt-PA delivered 4 hours poststroke onset as well as selective LOX-1 (BI-0115) and MMP-9 (JNJ0966) inhibitors given before rt-PA administration. Infarct size, perfusion, and hemorrhagic transformation were evaluated by 9.4-T magnetic resonance imaging, vascular and parenchymal MMP-9 activity via zymography, and neurological function was assessed using sensorimotor functioning testing. Human brain microvascular endothelial cells were exposed to hypoxia plus glucose deprivation/reperfusion (hypoxia plus glucose deprivation 3 hours/R 24 hours) and treated with ±rt-PA, ±MMP-9, and LOX-1 inhibitors. Barrier function was assessed via transendothelial electrical resistance, MMP-9 activity was determined with zymography, and LOX-1 and barrier gene expression/levels were measured using qRT-PCR and Western blot.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Stroke and subsequent rt-PA treatment increased edema, hemorrhage, MMP-9 activity, LOX-1 expression, and worsened neurological outcomes. LOX-1 inhibition improved neurological function, reduced edema, and improved endothelial barrier integrity. Elevated MMP-9 activity correlated with increased edema, infarct volume, and decreased neurological function. MMP-9 inhibition reduced MMP-9 activity and LOX-1 expression. In human brain microvascular endothelial cells, LOX-1/MMP-9 inhibition differentially attenuated MMP-9 levels, inflammation, and activation following hypoxia plus glucose deprivation/R.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings indicate that MMP-9 and LOX-1 inhibition attenuates negative aspects of ischemic stroke with an rt-PA therapy, thus resulting in improved neurological function. While no synergistic effect was observed with simultaneous LOX-1 and MMP-9 inhibition, a distinct interaction is evident.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38501247/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240320141009&v=2.18.0.post9+e462414">38501247</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323371>10.1161/CIRCRESAHA.123.323371</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38501247</guid>
<pubDate>Tue, 19 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Kajsa Arkelius</dc:creator>
<dc:creator>Trevor S Wendt</dc:creator>
<dc:creator>Henrik Andersson</dc:creator>
<dc:creator>Anaële Arnou</dc:creator>
<dc:creator>Michael Gottschalk</dc:creator>
<dc:creator>Rayna J Gonzales</dc:creator>
<dc:creator>Saema Ansar</dc:creator>
<dc:date>2024-03-19</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>LOX-1 and MMP-9 Inhibition Attenuates the Detrimental Effects of Delayed rt-PA Therapy and Improves Outcomes After Acute Ischemic Stroke</dc:title>
<dc:identifier>pmid:38501247</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323371</dc:identifier>
</item>
<item>
<title>Presence of microplastics in carotid plaques linked to cardiovascular events</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38499870/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240320141009&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Mar 18. doi: 10.1038/s41569-024-01015-z. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38499870/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240320141009&v=2.18.0.post9+e462414">38499870</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01015-z>10.1038/s41569-024-01015-z</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38499870</guid>
<pubDate>Tue, 19 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2024-03-19</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Presence of microplastics in carotid plaques linked to cardiovascular events</dc:title>
<dc:identifier>pmid:38499870</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01015-z</dc:identifier>
</item>
<item>
<title>Long-read sequencing provides insights into genetic influence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38499869/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240320141009&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Mar 18. doi: 10.1038/s41569-024-01012-2. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38499869/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240320141009&v=2.18.0.post9+e462414">38499869</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01012-2>10.1038/s41569-024-01012-2</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38499869</guid>
<pubDate>Tue, 19 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Cara Trivett</dc:creator>
<dc:date>2024-03-19</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Long-read sequencing provides insights into genetic influence</dc:title>
<dc:identifier>pmid:38499869</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01012-2</dc:identifier>
</item>
<item>
<title>Non-coding RNAs as therapeutic targets and biomarkers in ischaemic heart disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38499868/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240320141009&amp;v=2.18.0.post9+e462414
      <description>The adult heart is a complex, multicellular organ that is subjected to a series of regulatory stimuli and circuits and has poor reparative potential. Despite progress in our understanding of disease mechanisms and in the quality of health care, ischaemic heart disease remains the leading cause of death globally, owing to adverse cardiac remodelling, leading to ischaemic cardiomyopathy and heart failure. Therapeutic targets are urgently required for the protection and repair of the ischaemic...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Mar 18. doi: 10.1038/s41569-024-01001-5. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The adult heart is a complex, multicellular organ that is subjected to a series of regulatory stimuli and circuits and has poor reparative potential. Despite progress in our understanding of disease mechanisms and in the quality of health care, ischaemic heart disease remains the leading cause of death globally, owing to adverse cardiac remodelling, leading to ischaemic cardiomyopathy and heart failure. Therapeutic targets are urgently required for the protection and repair of the ischaemic heart. Moreover, personalized clinical biomarkers are necessary for clinical diagnosis, medical management and to inform the individual response to treatment. Non-coding RNAs (ncRNAs) deeply influence cardiovascular functions and contribute to communication between cells in the cardiac microenvironment and between the heart and other organs. As such, ncRNAs are candidates for translation into clinical practice. However, ncRNA biology has not yet been completely deciphered, given that classes and modes of action have emerged only in the past 5 years. In this Review, we discuss the latest discoveries from basic research on ncRNAs and highlight both the clinical value and the challenges underscoring the translation of these molecules as biomarkers and therapeutic regulators of the processes contributing to the initiation, progression and potentially the prevention or resolution of ischaemic heart disease and heart failure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38499868/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240320141009&v=2.18.0.post9+e462414">38499868</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01001-5>10.1038/s41569-024-01001-5</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38499868</guid>
<pubDate>Tue, 19 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Andrea Caporali</dc:creator>
<dc:creator>Maryam Anwar</dc:creator>
<dc:creator>Yvan Devaux</dc:creator>
<dc:creator>Rajesh Katare</dc:creator>
<dc:creator>Fabio Martelli</dc:creator>
<dc:creator>Prashant Kumar Srivastava</dc:creator>
<dc:creator>Thierry Pedrazzini</dc:creator>
<dc:creator>Costanza Emanueli</dc:creator>
<dc:date>2024-03-19</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Non-coding RNAs as therapeutic targets and biomarkers in ischaemic heart disease</dc:title>
<dc:identifier>pmid:38499868</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01001-5</dc:identifier>
</item>
<item>
<title>Protein glycosylation in cardiovascular health and disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38499867/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240320141009&amp;v=2.18.0.post9+e462414
      <description>Protein glycosylation, which involves the attachment of carbohydrates to proteins, is one of the most abundant protein co-translational and post-translational modifications. Advances in technology have substantially increased our knowledge of the biosynthetic pathways involved in protein glycosylation, as well as how changes in glycosylation can affect cell function. In addition, our understanding of the role of protein glycosylation in disease processes is growing, particularly in the context...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Mar 18. doi: 10.1038/s41569-024-00998-z. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Protein glycosylation, which involves the attachment of carbohydrates to proteins, is one of the most abundant protein co-translational and post-translational modifications. Advances in technology have substantially increased our knowledge of the biosynthetic pathways involved in protein glycosylation, as well as how changes in glycosylation can affect cell function. In addition, our understanding of the role of protein glycosylation in disease processes is growing, particularly in the context of immune system function, infectious diseases, neurodegeneration and cancer. Several decades ago, cell surface glycoproteins were found to have an important role in regulating ion transport across the cardiac sarcolemma. However, with very few exceptions, our understanding of how changes in protein glycosylation influence cardiovascular (patho)physiology remains remarkably limited. Therefore, in this Review, we aim to provide an overview of N-linked and O-linked protein glycosylation, including intracellular O-linked N-acetylglucosamine protein modification. We discuss our current understanding of how all forms of protein glycosylation contribute to normal cardiovascular function and their roles in cardiovascular disease. Finally, we highlight potential gaps in our knowledge about the effects of protein glycosylation on the heart and vascular system, highlighting areas for future research.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38499867/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240320141009&v=2.18.0.post9+e462414">38499867</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-00998-z>10.1038/s41569-024-00998-z</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38499867</guid>
<pubDate>Tue, 19 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>John C Chatham</dc:creator>
<dc:creator>Rakesh P Patel</dc:creator>
<dc:date>2024-03-19</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Protein glycosylation in cardiovascular health and disease</dc:title>
<dc:identifier>pmid:38499867</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-00998-z</dc:identifier>
</item>
<item>
<title>Correction to: Pharmacological Management of Cardiac Arrhythmias in the Fetal and Neonatal Periods: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38498614/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240320141009&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 19;149(12):e996. doi: 10.1161/CIR.0000000000001226. Epub 2024 Mar 18.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38498614/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240320141009&v=2.18.0.post9+e462414">38498614</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001226>10.1161/CIR.0000000000001226</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38498614</guid>
<pubDate>Mon, 18 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Pharmacological Management of Cardiac Arrhythmias in the Fetal and Neonatal Periods: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:38498614</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001226</dc:identifier>
</item>
<item>
<title>The Confusing Landscape of Cardiovascular Health Assessment, Promotion, and Prediction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38498613/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240320141009&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 19;149(12):914-916. doi: 10.1161/CIRCULATIONAHA.123.067982. Epub 2024 Mar 18.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38498613/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240320141009&v=2.18.0.post9+e462414">38498613</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067982>10.1161/CIRCULATIONAHA.123.067982</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38498613</guid>
<pubDate>Mon, 18 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Brendan M Everett</dc:creator>
<dc:date>2024-03-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>The Confusing Landscape of Cardiovascular Health Assessment, Promotion, and Prediction</dc:title>
<dc:identifier>pmid:38498613</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067982</dc:identifier>
</item>
<item>
<title>A Century of Heart Failure With Reduced Ejection Fraction: Mostly Drought, Followed by Rapid Progress</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38498612/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240320141009&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 19;149(12):899-901. doi: 10.1161/CIRCULATIONAHA.123.065468. Epub 2024 Mar 18.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38498612/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240320141009&v=2.18.0.post9+e462414">38498612</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065468>10.1161/CIRCULATIONAHA.123.065468</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38498612</guid>
<pubDate>Mon, 18 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Mariell Jessup</dc:creator>
<dc:date>2024-03-18</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>A Century of Heart Failure With Reduced Ejection Fraction: Mostly Drought, Followed by Rapid Progress</dc:title>
<dc:identifier>pmid:38498612</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065468</dc:identifier>
</item>





























</channel>
</rss>